Context Therapeutics Inc. · NASDAQ:CNTX
Context Therapeutics — Investor Presentation (July 2024)
29 slides from Context Therapeutics's investor presentation, Jul 10, 2024
Slide 1: Corporate Presentation: Advancing Medicines for Solid Tumors
July 2024 Corporate Presentation Advancing Medicines for Solid Tumors
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances
Slide 3: Building a T cell Engager (TCE) Pipeline
Building a T cell Engager (TCE) Pipeline Executive Summary Context Therapeutics Inc. - July 20243 TCEs are Gaining Momentum Recent TCE clinical data demonstrates promising efficacy and safety in solid tumors • Clinical activity across a broad range of targets, including Claudin 18.2, DLL3, PSMA, and
Slide 4: Pipeline
Executive Summary Pipeline Context Therapeutics Inc. - July 20244 PROGRAM TARGET ADDRESSABLE MARKET (U.S. ONLY) PRECLINICAL PHASE 1 PHASE 2 PHASE 3 RECENT & ANTICIPATED MILESTONES CTIM-76 Claudin 6 (CLDN6) > 50,000 patients IND cleared April 2024 First patient dose expected Mid 2024 CT-95 Mesothelin
Slide 5: CT-95 Acquisition Rationale
CT-95 Acquisition Rationale Executive Summary Context Therapeutics Inc. - July 20245 Portfolio Alignment • Bispecific T cell engager • Enriched in solid tumors High-quality Asset • Potentially first-in-class and best-in-class • Promising efficacy and safety in preclinical models Rapid Path to Clinic
Slide 6: Rationale for T Cell Engagers
Rationale for T Cell Engagers Context Therapeut ics Inc . - Ju ly 20246
Slide 7: T Cell Engaging Bispecific Antibodies
T Cell Engaging Bispecific Antibodies TCEs are engineered to activate an immune response against cancer Rationale for T Cell Engagers Context Therapeutics Inc. - July 20247 Mechanism of Action • T cell engagers are antibodies engineered to redirect the immune system’s T cells to recognize and kill c
Slide 8: Realizing the Full Potential of T cell Engagers (TCE)
Realizing the Full Potential of T cell Engagers (TCE) Rationale for T Cell Engagers Context Therapeutics Inc. - July 20248 Poor antigen selection Rapid T cell induction Short half-life Few TCE platforms; not customizable Tumor restricted antigens Premedication + step-dosing Therapeutic half-life Man
Slide 9: TCE Bispecifics are Gaining Momentum
TCE Bispecifics are Gaining Momentum Recent data supports promising efficacy with low rate of Grade ≥ 3 cytokine release syndrome (CRS) Asset Tarlatamab (AMG757) HPN328 IBI389 JANX007 Xaluritamig (AMG509) Bispecific Format HLE BiTE (truncated Fc) TriTAC (albumin) 1 +1 TRACTr (albumin) XmAb 2 x 1 Tar
Slide 10: CTIM-76 CLDN6 x CD3 bispecific antibody
CTIM-76 CLDN6 x CD3 bispecific antibody Context Therapeut ics Inc . - Ju ly 202410
Slide 11: CLDN6 is an Oncofetal Protein
CLDN6 is an Oncofetal Protein Oncofetal proteins are considered favorable candidates for immunotherapy • Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Increased expression across many solid tumors CTIM-76 Program Conte
Slide 12: CLDN6 Therapies Have the Potential to Reach a Large Patient Population
CLDN6 Therapies Have the Potential to Reach a Large Patient Population >50,000 patients per year in the US only in Relapse/Refractory (R/R) Setting CTIM-76 Program 12 Context Therapeutics Inc. - July 2024 Initial indications of interest based on: • CLDN6 prevalence • Patient population size • Observ
Slide 13: Developing a Highly Selective CLDN6 Antibody is Challenging
Developing a Highly Selective CLDN6 Antibody is Challenging CTIM-76 Program Context Therapeutics Inc. - July 202413 • CLDN6 antigen is conformationally dependent, which limits access to antibody-antigen binding • Antigen binding region is highly conserved with CLDN3, CLDN4, and CLDN9, making CLDN6-
Slide 14: CTIM-76: Claudin x CD3 T cell Engaging Bispecific Antibody
CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Established bispecific format • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is functionally monovalent to avoid aberrant T-cell activ
Slide 15: CTIM-76: Selectivity, Potency and In Vivo Efficacy
CTIM-76 Program CTIM-76: T cell engaging (TCE) CLDN6 x CD3 Bispecific Antibody Context Therapeutics Inc. - July 202415 Selectivity Potency In Vivo Efficacy • CTIM-76 CLDN6 EC50 of 3.41 nM (binding) • CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 • CLDN3/4/6/9 were transiently transfected in H
Slide 16: CTIM-76 Phase 1a/b Study
CTIM-76 Phase 1a/b Study An open-label, multi-center, dose escalation / expansion, safety, and PK study • Target population ̶ Platinum resistant ovarian cancer ̶ Endometrial and testicular cancer relapsed to standard of care • Biomarker stratification ̶ CLDN6+ positive (10% ≥ 1+) ovarian and endomet
Slide 17: CTIM-76 Competitive Landscape
CTIM-76 Competitive Landscape CLDN6 x CD3 T Cell Engaging Bispecifics CTIM-76 XmAb541 AMG794 SAIL66 NBL-028 Undisclosed Company Context Xencor Amgen Chugai NovaRock Beigene Stage IND Open IND Open Ph 1 (active, not recruiting)1 Ph 1 Ph 1 IND filed Dec 2023 Bispecific Format 1 + 1 2 + 1 HLE Bite Dual
Slide 18: CT-95 MSLN x CD3 bispecific antibody
CT-95 MSLN x CD3 bispecific antibody Context Therapeut ics Inc . - Ju ly 202418
Slide 19: MSLN Therapies Have the Potential to Reach a Large Patient Population
MSLN Therapies Have the Potential to Reach a Large Patient Population >100,000 patients per year in the US only in Relapse/Refractory (R/R) Setting CT-95 Program 19 Context Therapeutics Inc. - July 2024 Selected Cancer indications Incidence R/R Incidence MSLN Positive MLSN Med/High Patient Populatio
Slide 20: MSLN Target Biology
MSLN Target Biology Fragmented (shed) MSLN in tumor microenvironment requires a creative solution to overcome CT-95 Program Context Therapeutics Inc. - July 202420 • MSLN is bound to tumor cells via a GPI-anchor • Like many GPI-anchored proteins, MLSN can be cut into smaller fragments1,2 • Fragmente
Slide 21: CT-95: MSLN x CD3 T cell Engaging Bispecific Antibody
CT-95: MSLN x CD3 T cell Engaging (TCE) Bispecific Antibody Novel design to overcome mesothelin (MSLN) sink • Binds to membrane-proximal MSLN • Cooperative binding results in high affinity binding of CT-95 to tumor Potentially wide therapeutic window • No crosslinking with shed MSLN, mitigating off-
Slide 22: Two-Pronged Approach to Overcoming Soluble MSLN Sink Challenge
Two-Pronged Approach to Overcoming Soluble MSLN Sink Challenge CT-95 Program Context Therapeutics Inc. - July 202422 Binds MSLN Epitope Close to Cell Surface Activates T cells Through Cooperative Binding + CD3 Potent T cell activationNo T cell activation No crosslinking with shed MSLN MSLN on tumor
Slide 23: CT-95 Intended to Overcome MSLN Sink
Medium MSLN Expression 4k copies per cell High MSLN Expression 27k copies per cell CT-95 Intended to Overcome MSLN Sink Competitor program (HPN-536, Harpoon Therapeutics) binds to MSLN fragments in a dose proportional manner, limiting therapeutic exposure CT-95 Program Context Therapeutics Inc. - Ju
Slide 24: CT-95 is Highly Active and Well Tolerated Across In Vivo Models
CT-95 is Highly Active and Well Tolerated Across In Vivo Models Complete tumor regressions in mice at doses ≤ 0.05 mg/kg CT-95 Program Context Therapeutics Inc. - July 202424 Primary Lesion Model Metastatic Lesion Model OVCAR3 pre-passaged in mice to generate aggressive, metastatic tumor model Ovari
Slide 25: CT-95 Competitive Landscape
CT-95 Program CT-95 Competitive Landscape Context Therapeutics Inc. - July 202425 2nd Generation 1st Generation Company Context Zymeworks3 Numab4 Navrogen5 Harpoon AbbVie Asset CT-95 ZW171 NM28-2746 NAV-003 HPN-536 ABBV-428 Format 2 + 2 2 + 1 Trispecific 2 + 2 TriTAC 2 + 2 PK Enhancement Fc Fc Album
Slide 26: Corporate
Corporate 26 Context Therapeut ics Inc . - Ju ly 2024
Slide 27: Experienced Leadership Team
Corporate Experienced Leadership Team • Experienced team • Our management team is supported by a Board with strong public company operating and governance experience Focus on Execution Martin Lehr CEO and Director Alex Levit, Esq Chief Legal Officer Jennifer Minai, CPA Chief Financial Officer Chris
Slide 28: Investment Highlights
Corporate Investment Highlights (Nasdaq: CNTX) Solid Tumors Large Unmet Need Claudin 6 + Mesothelin High-Value Targets CTIM-76 first patient mid-2024 CT-95 first patient Q1 2025 Anticipated Milestones Oncology experience Strong Team Expected cash runway into 2028 Cash Runway Context Therapeutics Inc
Slide 29: Advancing Medicines for Solid Tumors
Advancing Medicines for Solid Tumors © Context Therapeutics 2024
Context Therapeutics — Investor Presentation (July 2024) on 6ix